Oxitope Pharma and Arxx Therapeutics – companies with a shared goal of utilizing the innate immune system to discover and develop disease-modulating therapies – announced today their merger to form Calluna Pharma today. Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor. This new company will combine expertise in the field of innate immunity, based on damage-associated molecular patterns (DAMPs), with a pipeline of selective antibodies that target inflammatory and fibrotic indications, including several first-in-class clinical candidates.
Calluna is transforming novel therapies that harness the transformative potential of the body’s immune system. And the company’s unique approach involves precision targeting of upstream innate immune amplifiers, enabling disruption of a comprehensive range of disease-associated downstream signaling pathways while maintaining a favorable safety profile. So Calluna has developed a robust pipeline of selective antibodies targeting immunological diseases. These include novel therapeutic candidates that fulfill unmet clinical needs across a spectrum of diseases driven by acute or chronic inflammation and non-resolving tissue fibrosis.
Calluna has four promising therapies in its pipeline. The clinical stage lead program CAL101 is a monoclonal antibody that neutralizes the bioactivity of S100A4, a DAMP protein implicated in serious and life-threatening diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis, and severe (steroid insensitive) asthma. And of particular interest is another of its programs CAL102, a monoclonal antibody neutralizing oxidized phospholipids – these play a significant role in onset and progression of a wide range of acute and chronic inflammatory and fibrotic diseases. CAL102 demonstrated efficacy in several preclinical disease models.
The company’s board of directors will include John Montana, Operating Partner (Forbion), as Chief Executive Officer, Antoine Boulanger, Principal (Forbion), Susanne Stuffers (p53), Farzad Abdi-Dezfuli General Partner (Sarsia), and Marco Boorsma, General Partner (Forbion) as Chairman. And the company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years.
KEY QUOTES:
“In joining forces, these two key players in the innate immunology space have created an exciting new clinical company that has four promising therapies in its pipeline with excellent preclinical proof-of-concept data. By innovating beyond traditional treatment strategies, Calluna offers clinical candidates with superior efficacy, improved patient tolerance, and minimal adverse side effects which have real potential to redefine patient outcomes.”
– John Montana, PhD., Chief Executive Officer of Calluna Pharma
“The merger of Oxitope Pharma and Arxx Therapeutics to create Calluna Pharma is a prime example of our Forbion Ventures Fund’s strategy where we both build new and enable existing companies. As a result, we recognized the strength of combining these two companies’ pioneering approaches to disrupt the treatment of inflammatory and fibrotic diseases, the complementarity of management skills, and the resulting robust clinical pipeline. We look forward to continuing our support of potentially life changing clinical assets moving into the next phases of clinical development.”
– Antoine Boulanger, PhD., Principal at Forbion
“Sarsia and p53 strive to bring cutting edge ideas and therapies from early-phase to clinical development and beyond to benefit patients and transform people’s lives. Calluna Pharma epitomizes this, and we are enthusiastic to join forces with Forbion and to contribute to the success of this new entity.”
– Sveinung Hole, MBA, Managing Partner at Sarsia (ex-Chair at Arxx Therapeutics) and Susanne Stuffers MD, PhD, Managing Partner at p53
